Characteristic (reference group) Time to discontinuation Overall survival Progression-free survival HR 95% CI HR 95% CI HR 95% CI Everolimus-based therapy (chemotherapy) unadjusted 0.36 (0.27, 0.47) 0.49 (0.30, 0.78) 0.74 (0.55, 1.01) 0.0582 Everolimus-based therapy (chemotherapy) adjusted 0.34 (0.25, 0.45) 0.37 (0.22, 0.63) 0.70 (0.50, 0.97) Index therapy line (First line) Second line 1.11 (0.70, 1.75) 0.657 1.41 (0.65, 3.05) 0.380 1.26 (0.77, 2.07) 0.357 Third line and above 0.98 (0.61, 1.56) 0.918 1.07 (0.46, 2.50) 0.875 1.30 (0.78, 2.15) 0.314 Disease status (de novo) Recurrent with adjuvant ET 1.79 (1.11, 2.89) 1.46 (0.62, 3.44) 0.391 1.74 (1.04, 2.93) Recurrent without adjuvant ET 0.63 (0.34, 1.17) 0.144 0.69 (0.24, 1.99) 0.489 0.47 (0.23, 0.98) Age at index therapy initiation 1.00 (0.97, 1.03) 0.911 1.07 (1.02, 1.12) 1.01 (0.98, 1.04) 0.355 Race (all other races) White 0.68 (0.51, 0.91) 0.92 (0.55, 1.52) 0.739 0.77 (0.56, 1.06) 0.111 Insurance at mBC diagnosis (neither insurance) Private 1.79 (0.95, 3.39) 0.072 1.49 (0.44, 5.08) 0.525 2.36 (1.07, 5.21) Medicare only 1.83 (0.91, 3.66) 0.089 1.04 (0.29, 3.81) 0.949 2.28 (0.99, 5.25) 0.053 CCI at index therapy initiation 1.00 (0.87, 1.14) 0.957 1.04 (0.85, 1.28) 0.713 0.95 (0.82, 1.12) 0.561 Sites of metastasis at index therapy initiation Bone 1.42 (1.06, 1.91) 1.28 (0.76, 2.13) 0.351 1.90 (1.34, 2.69) Visceral 1.80 (1.10, 2.96) 1.36 (0.56, 3.27) 0.498 1.83 (1.08, 3.12) Performance status at index therapy initiation (ECOG 0) ECOG 1 1.10 (0.76, 1.60) 0.600 1.78 (0.83, 3.81) 0.137 1.78 (1.14, 2.77) ECOG 2 2.29 (1.36, 3.86) 4.73 (1.89, 11.84) 4.13 (2.31, 7.40) ECOG 3 20.29 (7.05, 58.35) 264.30
(63.54, 1,099.46) 49.13 (16.74, 144.24) None 1.28 (0.79, 2.05) 0.317 3.36 (1.33, 8.49) 2.10 (1.22, 3.62) Previous chemotherapy treatment in mBC setting 1.39 (0.92, 2.11) 0.121 2.51 (1.22, 5.15) 1.21 (0.76, 1.92) 0.424 Duration from initiation of last adjuvant ET to mBC diagnosis 0.99 (0.99, 1.00) 1.00 (0.99, 1.01) 0.961 1.00 (0.99, 1.00) 0.173
